Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Combined vaccine for inhibiting and / or preventing type A streptococcal infection

A type A streptococcus and streptococcus technology, applied in antibacterial drugs, bacterial antigen components, etc., can solve problems such as hindering vaccine development, lack of serotype crossover, and difficulty in developing vaccines

Active Publication Date: 2015-11-18
HAIKOU PHARMA FACTORY
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The research and development of Streptococcus A vaccine started as early as the 1920s but has not yet come out. Two important reasons have hindered the development of vaccines: First, there are many serotypes of Streptococcus A, and each serotype lacks crossover, making it difficult to develop a vaccine. Vaccine against all serotypes
Streptococcus A is divided into more than 150 serotypes according to the difference of the M protein of its cell wall, and the number is constantly increasing. It is difficult for a vaccine designed for one serotype to work against another serotype, which has become the primary reason for restricting the development of vaccines.
Second, streptococcal infection is closely related to autoimmune diseases, and vaccines have the risk of causing autoimmune diseases, which greatly hinders the process of vaccine development
Although sortase A immunization also induces the production of antibodies, because it is located in the cell wall, antibodies cannot recognize it and thus cannot exert immune protection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined vaccine for inhibiting and / or preventing type A streptococcal infection
  • Combined vaccine for inhibiting and / or preventing type A streptococcal infection
  • Combined vaccine for inhibiting and / or preventing type A streptococcal infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Embodiment 1, the preparation of combined vaccine component sortase A and C5a protease

[0062] 1. Preparation of sortase A

[0063] 1. Preparation of recombinant expression vector

[0064] 1) Using the genomic DNA of type A Streptococcus M1 as a template, perform PCR amplification with a primer pair composed of F1 and R1 to obtain a 516bp PCR amplification product, which is the sortase A gene SrtA.

[0065] F1: 5'-CTTA CATATG GTCTTGCAAGCACAAATGG-3';

[0066] R1: 5'-ATGTT CTCGAG CTAGGTAGATACTTGGTTATAAGA-3'.

[0067] 2), using restriction endonucleases NdeI and XhoI to double digest the PCR amplified product of step 1, and reclaim the digested product.

[0068] 3) The vector pET28a(+) was double digested with restriction endonucleases NdeI and XhoI, and the vector backbone of about 6000 bp was recovered.

[0069] 4) Ligate the digested product of step 2 with the vector backbone of step 3 to obtain the recombinant plasmid pET28a-SrtA.

[0070] After sequencing, t...

Embodiment 2

[0109] Embodiment 2, the functional research of combined vaccine

[0110] 1. The immune protection of the combined vaccine against Streptococcus A

[0111] The immunogens are grouped as follows:

[0112] Sortase A plus CTB group (SrtA): the sortase A prepared in Example 1 and the adjuvant CTB were mixed according to the mass ratio of 10:1, and immunized, and the immunization dose was 10 μg sortase A / time / piece;

[0113] C5a protein plus CTB group (SCPA): the C5a protease prepared in Example 1 and the adjuvant CTB were mixed according to the mass ratio of 20:1, and immunized, and the immunization dose was 20 μg C5a protein / time;

[0114] Combined vaccine plus CTB group (SrtA / SCPA): Combined vaccine immunization prepared in Example 1, immunization dose is 20 μg C5a protein / time;

[0115] Streptococcus A full bacteria group (GAS): Type A Streptococcus M1 type immunity, the immune dose is 5×10 7 cfu / time;

[0116] PBS group: use PBS (10mMNa 2 HPO 4 , 1.8mMKH 2 PO 4 , 140mM...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a combined vaccine for inhibiting and / or preventing type A streptococcal infection. The present invention provides a composition for inhibiting streptococcus and / or preventing streptococcal infection, and the composition comprise an immunogen. The immunogen is one of the following 1)-4): 1) the immunogen comprises a sortase A and a C5a protease; 2) the immunogen comprises a sortase A solution and a C5a protease solution; 3) the immunogen comprise a fusion protein containing sortase A and a fusion protein containing C5a protease; and 4) the immunogen comprises a junctional complex of sortase A and polysaccharide and a junctional complex of C5a protease and polysaccharide. The specific amino acid sequence of the sortase A is the N-terminal amino acid residues from site No.22 to No.189 of a sequence 2; and the amino acid sequence of the C5a protease is a sequence 4 in the sequence table. The combined vaccine can be applied to prevention and treatment of mucosal system infections caused a variety of Gram-positive bacteria.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to a combined vaccine for inhibiting and / or preventing type A streptococcus infection. Background technique [0002] Group A streptococci (hereinafter referred to as Streptococcus A) is a normal flora of the human upper respiratory tract and one of the common clinical Gram-positive opportunistic pathogens, which can cause a variety of diseases, including tonsillitis in mild cases , pharyngitis and various types of skin and soft tissue infections; severe cases are seriously life-threatening, such as pneumonia, bacteremia, toxic shock syndrome and acute necrotizing fasciitis. Streptococcus A is ubiquitous in the tonsils of humans. Once it enters the wound, it has a strong reproductive ability in the human body, can quickly produce toxins, erode muscles and body tissues, and cause patients to become disabled, shock, or even die. "Man-eating fungus". Recurrent streptococcal tonsillitis can lea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/116A61K39/09A61P31/04
Inventor 王北难陈宪洋毕帅范鑫王小爽
Owner HAIKOU PHARMA FACTORY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com